Salvat and WraSer Pharmaceuticals have entered into an exclusive license agreement to market Salvat’s Cetraxal in the US, for a period of ten years.
The company said that Cetraxal is the only ciprofloxacin-alone solution approved by the FDA for treating AOE, providing high efficacy without risk from steroids or preservatives. Cetraxal is available in a single-dispensing container that ensures safe and accurate dosing.
Heath Wray, President of WraSer Pharmaceuticals, said: “WraSer is extremely excited to bring this new product to the US market. We are confident that patients will appreciate the ease of use with the single-dose dispenser, and physicians will be confident in a safe, effective treatment for swimmer’s ear utilizing a steroid-free, proven antibiotic therapy.”
Earlier in May 2009, Cetraxal had received FDA approval as a new treatment for Acute Otitis Externa (AOE) or swimmer’s ear.